New diagnostic thresholds for ultrasound use in pregnancy may help avoid inadvertent harm to fetus.
New criteria for use of ultrasonography in determining when a first trimester pregnancy is nonviable have been issued by a panel of experts and published in the New England Journal of Medicine.
Fifteen experts from the fields of radiology, obstetrics-gynecology, and emergency medicine made the recommendations to help avoid the possibility of physicians causing inadvertent harm to a potentially normal pregnancy.
Some key points:
· In order for a pregnancy to be diagnosed as nonviable in the first trimester, the embryo must measure at least seven millimeters without a heartbeat, up from previous accepted measurement of five millimeters.
· The standard for nonviability based on the size of the gestational sac without an embryo should be raised from 16 to 25 millimeters.
· The commonly used “discriminatory level” of the pregnancy blood test is not reliable for excluding a viable pregnancy.
In addition, the panelists cautioned that there is no rush to diagnose a miscarriage and that physicians should be careful to avoid any actions that could damage in intrauterine pregnancy based on a single blood test, if the ultrasound findings are inconclusive, and the woman is stable.
“These are critical guidelines and will help all physicians involved in the care of the emergency patient,” panelist Michael Blaivas, MD, said in a release. “They represent an up-to-date and accurate scientific compass for navigating the pathway between opposing forces felt by the emergency physician and his or her consultants who are concerned about the potential morbidity and mortality of an untreated ectopic pregnancy in a patient who may be lost to follow-up, but yet must ensure the safety of an unrecognized early normal pregnancy.”
Blaivas is an emergency medicine physician affiliated with the University of South Carolina.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.